HUE040230T2 - Egy alkálikus foszfatáz feldolgozási folyamata - Google Patents

Egy alkálikus foszfatáz feldolgozási folyamata

Info

Publication number
HUE040230T2
HUE040230T2 HUE15703640A HUE15703640A HUE040230T2 HU E040230 T2 HUE040230 T2 HU E040230T2 HU E15703640 A HUE15703640 A HU E15703640A HU E15703640 A HUE15703640 A HU E15703640A HU E040230 T2 HUE040230 T2 HU E040230T2
Authority
HU
Hungary
Prior art keywords
alkaline phosphatase
downstream processing
downstream
processing
phosphatase
Prior art date
Application number
HUE15703640A
Other languages
English (en)
Inventor
Luigi Johannes Cornelius Jonk
Stephen Edward Connor
Den Berg Erik Jan Van
Elsas Andrea Van
Abhinav Alok Shukla
Heather Bethea Horne
Susan Cook
Timothy Martin Kelly
Victoria Anne Dowling
Mialy Fanjamalala Ramaroson
Original Assignee
Am Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Am Pharma Bv filed Critical Am Pharma Bv
Publication of HUE040230T2 publication Critical patent/HUE040230T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
HUE15703640A 2014-01-24 2015-01-26 Egy alkálikus foszfatáz feldolgozási folyamata HUE040230T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14152542 2014-01-24

Publications (1)

Publication Number Publication Date
HUE040230T2 true HUE040230T2 (hu) 2019-02-28

Family

ID=49989634

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE15703640A HUE040230T2 (hu) 2014-01-24 2015-01-26 Egy alkálikus foszfatáz feldolgozási folyamata
HUE18190484A HUE051470T2 (hu) 2014-01-24 2015-01-26 Egy alkalikus foszfatáz feldolgozási folyamata

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE18190484A HUE051470T2 (hu) 2014-01-24 2015-01-26 Egy alkalikus foszfatáz feldolgozási folyamata

Country Status (12)

Country Link
US (2) US10570380B2 (hu)
EP (2) EP3097188B1 (hu)
JP (3) JP6713147B2 (hu)
CN (3) CN106459143A (hu)
CA (1) CA2936829A1 (hu)
DK (2) DK3097188T3 (hu)
ES (2) ES2810813T3 (hu)
HU (2) HUE040230T2 (hu)
PL (2) PL3461891T3 (hu)
PT (1) PT3461891T (hu)
SI (2) SI3097188T1 (hu)
WO (1) WO2015112015A1 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE039448T2 (hu) 2004-04-21 2018-12-28 Alexion Pharma Inc Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására
BR112016017041B1 (pt) 2014-01-24 2023-09-26 Am-Pharma B.V Proteína quimérica isolada, vetor, método para produzir a proteína quimérica isolada e composição
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
KR102644116B1 (ko) 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 알칼린 포스파타제의 제조
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
MX2018011833A (es) 2016-04-01 2019-02-13 Alexion Pharma Inc Tratamiento para la debilidad muscular con fosfatasas alcalinas.
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
WO2019139891A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2020243697A1 (en) 2019-05-31 2020-12-03 Rhogen Biotech Llc Compositions and methods for detoxifying bacterial endotoxins
KR20230088811A (ko) * 2020-10-23 2023-06-20 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제의 제조 동안 총 시알산 함량(tsac)을 제어하는 방법

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328918D0 (en) * 1983-10-28 1983-11-30 Unilever Plc Alkaline phosphatase
DE69127482T2 (de) 1990-02-07 1998-03-19 Abbott Lab Alkalische Phosphatase mit verbesserter spezifischer Aktivität zur Verwendung in Indikatorreagenzien
EP0584343B1 (en) 1992-03-10 1999-01-20 La Jolla Cancer Research Foundation Recombinant calf intestinal alkaline phosphatase
AU698101B2 (en) 1993-06-01 1998-10-22 Cortex Pharmaceuticals, Inc. Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
AU4835693A (en) 1993-08-13 1995-03-14 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
CA2176709A1 (en) 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
US20020055098A1 (en) 1994-04-18 2002-05-09 Joseph Szasz Thermostable alkaline phosphatases
JP3625503B2 (ja) * 1994-11-11 2005-03-02 旭化成ファーマ株式会社 臨床検査用複合酵素含有組成物
EP0851772A1 (en) 1995-06-06 1998-07-08 Gensci Regeneration Laboratories, Inc. Modified osteogenic materials
FR2736065B1 (fr) 1995-06-29 1997-09-19 Commissariat Energie Atomique Phosphatases alcalines bacteriennes modifiees et leurs applications.
DE69625873T2 (de) * 1995-10-27 2003-12-24 Amersham Biosciences Corp Thermostabile, alkalische Phosphatase aus Rhodothermus Marinus
JP3488327B2 (ja) 1995-12-21 2004-01-19 よつ葉乳業株式会社 牛乳脂肪球膜含有画分の製造法
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
DE19819962A1 (de) 1998-05-05 1999-11-11 Roche Diagnostics Gmbh Hochaktive alkalische Phosphatase
WO2000037943A1 (en) 1998-12-21 2000-06-29 Stichting Voor De Technische Wetenschappen Diagnosis of sepsis using the lps-binding moiety of alkaline phosphatase
JP2000350596A (ja) 1999-06-11 2000-12-19 Toyobo Co Ltd 分泌性アルカリフォスファターゼの選択的活性測定方法
ATE327751T1 (de) 2000-01-31 2006-06-15 Pfizer Prod Inc Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
CA2415954A1 (en) 2000-07-19 2003-01-17 Kazuhiro Maeda Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
DE10101793A1 (de) 2001-01-17 2002-08-01 Manfred Nilius Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen
WO2002057430A2 (en) 2001-01-20 2002-07-25 Cardion Ag Pluripotent adult stem cells derived from regenerative tissue
WO2002098433A1 (fr) 2001-06-01 2002-12-12 Ajinomoto Co., Inc. Medicaments pour les maladies intestinales
JP3507890B2 (ja) 2001-06-07 2004-03-15 大阪大学長 Ｓｈｅｗａｎｅｌｌａｓｐ．ＳＩＢ１株由来の新規なアルカリフォスファターゼ
US7157260B2 (en) 2001-07-26 2007-01-02 Japan Science & Technology Agency Nicotianamine synthase and gene encoding the same
JP4169966B2 (ja) 2001-11-14 2008-10-22 株式会社ヤクルト本社 炎症性腸疾患予防治療剤
CN1425766A (zh) 2001-12-19 2003-06-25 复旦大学 一种多肽——人含碱性磷酸酶活性位点的蛋白－9.24和编码这种多肽的多核苷酸
WO2004044178A2 (en) 2002-11-13 2004-05-27 Genentech, Inc. Methods and compositions for diagnosing dysplasia
US7048914B2 (en) 2002-12-12 2006-05-23 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
WO2004056987A1 (en) 2002-12-23 2004-07-08 Rijksuniversiteit Groningen Modulation of the thioredoxin pathway
WO2004083432A1 (en) 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
JP4305071B2 (ja) 2003-06-30 2009-07-29 株式会社ニコン 信号補正方法
JP2005065564A (ja) 2003-08-22 2005-03-17 Hiroshi Ueda センサー蛋白質
US20110142817A1 (en) 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
EP1713541B1 (en) 2004-02-04 2017-03-22 AM-Pharma B.V. Use of alkaline phosphatase for the detoxification of lps
AU2006220772A1 (en) 2005-03-04 2006-09-14 Verenium Corporation Nucleic acids and proteins and methods for making and using them
US20070059300A1 (en) 2005-09-12 2007-03-15 Zoltan Laboratories Llc Compounds and compositions to control abnormal cell growth
US7695714B2 (en) 2005-12-28 2010-04-13 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals
US20070280922A1 (en) 2006-06-06 2007-12-06 Zoltan Kiss Consulting Combinations of human proteins to enhance viability of stem cells and progenitor cells
US7718170B2 (en) 2006-08-21 2010-05-18 Essential Skincare, Llc Alkaline phosphatase compositions to reduce skin cancer
EP1952823A1 (en) * 2007-01-30 2008-08-06 AM-Pharma B.V. The use of alkaline phosphatase in the treatment of reduced renal function
WO2008104199A1 (en) 2007-03-01 2008-09-04 Gelato Corporation N.V. Use of ecto-phosphatases for the treatment of (acute) myocardial infarction
EP1985697A1 (en) 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
EP2030980A1 (en) 2007-08-28 2009-03-04 AM-Pharma B.V. Mutants of lactoferrin
ES2421717T3 (es) 2008-02-29 2013-09-05 Alloksys Life Science B V Fosfatasa alcalina para aumentar la actividad del sistema inmune en un mamífero con riesgo de enfermedades inflamatorias
EP2291372A4 (en) 2008-05-19 2012-04-25 Burnham Inst Medical Research MODULATORS OF ALKALINE PHOSPHATASE FROM DARM AND APPLICATIONS THEREOF
EP2334306B1 (en) 2008-08-29 2014-04-02 The General Hospital Corporation Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase
US9453045B2 (en) 2010-03-30 2016-09-27 Octapharma Ag Process for the purification of a growth factor protein
JP2012196170A (ja) * 2011-03-22 2012-10-18 Sanyo Chem Ind Ltd セルラーゼ組成物及びこのセルラーゼ組成物を含有する洗剤組成物
ES2828987T3 (es) 2011-06-08 2021-05-28 Am Pharma Bv El uso de fosfatasa alcalina para preservar la función renal
JP2014522868A (ja) * 2011-07-29 2014-09-08 イレブン・バイオセラピユーテイクス・インコーポレイテツド 精製タンパク質

Also Published As

Publication number Publication date
SI3461891T1 (sl) 2020-09-30
CN112048491A (zh) 2020-12-08
EP3461891A1 (en) 2019-04-03
JP2017505613A (ja) 2017-02-23
CA2936829A1 (en) 2015-07-30
WO2015112015A1 (en) 2015-07-30
ES2810813T3 (es) 2021-03-09
JP2022001061A (ja) 2022-01-06
JP6713147B2 (ja) 2020-06-24
EP3461891B1 (en) 2020-07-01
HUE051470T2 (hu) 2021-03-01
US20200063112A1 (en) 2020-02-27
SI3097188T1 (sl) 2018-10-30
EP3097188B1 (en) 2018-08-29
PT3461891T (pt) 2020-07-30
DK3461891T3 (da) 2020-08-10
DK3097188T3 (en) 2018-10-08
JP7039645B2 (ja) 2022-03-22
US10570380B2 (en) 2020-02-25
ES2688066T3 (es) 2018-10-30
CN106459143A (zh) 2017-02-22
JP2020127427A (ja) 2020-08-27
PL3097188T3 (pl) 2018-11-30
PL3461891T3 (pl) 2020-11-16
WO2015112015A8 (en) 2016-03-03
US20170009217A1 (en) 2017-01-12
CN112029753A (zh) 2020-12-04
EP3097188A1 (en) 2016-11-30
JP7449266B2 (ja) 2024-03-13

Similar Documents

Publication Publication Date Title
SI3461891T1 (sl) Dolvodno procesiranje alkalne fosfataze
GB2528699B (en) Image processing
IL250089A0 (en) Metrology of multiple sampling processes
GB2524249B (en) Image Processing
GB201404734D0 (en) Image processing
GB2529705B (en) Message processing
GB2525637B (en) Message Processing
GB2533581B (en) Image processing
GB201519344D0 (en) Oat processing
EP3158817A4 (en) Reduced-latency processing of voice-over-lte calls
HK1255588B (zh) 處理系統
GB2527553B (en) Laser processing
GB2552406B (en) Laser processing
GB201420737D0 (en) Graphic processing systems
HK1223624A1 (zh) 替諾福韋的固體形式
SG10201504344VA (en) Component processing
GB201406165D0 (en) Call processing
PL3111151T3 (pl) Sposób działania obrotowego pieca do wytwarzania spoiw hydraulicznych
GB2522904B (en) Method of making an airdam
GB201521655D0 (en) Object processing
GB2526663B (en) Processing of poultry
GB201400932D0 (en) Location of criticality
GB201402298D0 (en) Processing of microalgae
GB201521201D0 (en) Processing of poultry
GB201407167D0 (en) Processing of biomass